INCY Stock Price Chart
INCY Earnings
Incyte Corp
$98.55
0.81%
$0.79
At close: May 08, 16:00:00 GMT-4
$98.56
0.01%
$0.01
Post-market: May 08, 20:00:00 GMT-4
Back
Incyte Corp (INCY) Earnings
Key Stats
Prev.Close
$97.75
Open
$98.59
Day's Range
$97.49 - $99.87
52 week range
$56.13 - $112.29
Volume
620.9K
Avg.Volume
1.8M
Dividend yield
--
EPS (TTM)
6.40
Market Cap
$19.6B
What is INCY?
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,844 full-time employees. The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
